Graham H Jackson

Graham H Jackson

UNVERIFIED PROFILE

Are you Graham H Jackson?   Register this Author

Register author
Graham H Jackson

Graham H Jackson

Publications by authors named "Graham H Jackson"

Are you Graham H Jackson?   Register this Author

78Publications

1295Reads

-Profile Views

Physicians, paraproteins and progress: diagnosis and management of myeloma.

Br J Hosp Med (Lond) 2019 Feb;80(2):91-98

Professor of Haematology, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

View Article

Download full-text PDF

Source
http://www.magonlinelibrary.com/doi/10.12968/hmed.2019.80.2.
Publisher Site
http://dx.doi.org/10.12968/hmed.2019.80.2.91DOI Listing
February 2019

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Nat Commun 2019 01 10;10(1):213. Epub 2019 Jan 10.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08107-8
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08107-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328616PMC
January 2019

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Nat Commun 2018 09 13;9(1):3707. Epub 2018 Sep 13.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-04989-w
Publisher Site
http://dx.doi.org/10.1038/s41467-018-04989-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137048PMC
September 2018

Active multiple myeloma suppresses and typically eliminates coexisting MGUS.

Br J Cancer 2017 Sep 20;117(6):835-839. Epub 2017 Jul 20.

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589985PMC
September 2017

Telomere length is a critical determinant for survival in multiple myeloma.

Br J Haematol 2017 07 24;178(1):94-98. Epub 2017 Mar 24.

Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14643DOI Listing
July 2017

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Nat Commun 2017 02 6;8:14175. Epub 2017 Feb 6.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms14175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303820PMC
February 2017

Evolving concepts in tumour lysis syndrome management - response to Ayed et al.

Br J Haematol 2016 05 27;173(3):486-7. Epub 2015 Jul 27.

Department of Haematology, Derriford Hospital, Plymouth, Devon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13616DOI Listing
May 2016

Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.

Biochem Pharmacol 2016 Mar 12;103:29-39. Epub 2016 Jan 12.

Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2015.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071433PMC
March 2016

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

J Clin Oncol 2015 Nov 17;33(33):3911-20. Epub 2015 Aug 17.

Brian A. Walker, Eileen M. Boyle, Christopher P. Wardell, Alex Murison, Dil B. Begum, Nasrin M. Dahir, Paula Z. Proszek, David C. Johnson, Martin F. Kaiser, Lorenzo Melchor, Lauren I. Aronson, Charlotte Pawlyn, Fabio Mirabella, John R. Jones, Annamaria Brioli, Faith E. Davies, and Gareth J. Morgan, The Institute of Cancer Research, London; Matthew Scales, The Institute of Cancer Research, Surrey; David A. Cairns, Walter M. Gregory, and Ana Quartilho, University of Leeds; Gordon Cook, St James's University Hospital, Leeds; Mark T. Drayson, University of Birmingham, Birmingham; Nigel Russell, Nottingham University Hospital, Nottingham; Graham H. Jackson, Newcastle University, Newcastle upon Tyne, United Kingdom; Aneta Mikulasova, Masaryk University, Brno, Czech Republic; and Xavier Leleu, Hôpital C. Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.1503
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.1503DOI Listing
November 2015

Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells.

Biol Open 2015 Oct 12;4(11):1436-47. Epub 2015 Oct 12.

Institute for Cellular and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/bio.014308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728365PMC
October 2015

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.

Genes Chromosomes Cancer 2015 Feb 7;54(2):91-8. Epub 2014 Oct 7.

Division of Molecular Pathology, The Institute of Cancer Research, London, UK; Service des maladies du Sang, Hopital Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310140PMC
February 2015

Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Clin Cancer Res 2013 Nov 30;19(21):6030-8. Epub 2013 Aug 30.

Authors' Affiliations: Institute of Cancer Research, Royal Marsden Hospital, London; Clinical Trials Research Unit, University of Leeds; St James's University Hospital, Leeds; University of Birmingham, Birmingham; Wessex Regional Genetics Laboratory, University of Southampton, Salisbury; and University of Newcastle, Newcastle-upon-Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2013/08/
Web Search
http://clincancerres.aacrjournals.org/content/19/21/6030.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-3211DOI Listing
November 2013

The impact of response on bone-directed therapy in patients with multiple myeloma.

Blood 2013 Oct 23;122(17):2974-7. Epub 2013 Aug 23.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-04-498139DOI Listing
October 2013

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Leuk Lymphoma 2013 Sep 23;54(9):1975-81. Epub 2013 Jan 23.

Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.760736DOI Listing
September 2013

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

Br J Haematol 2013 Apr 29;161(2):291-4. Epub 2013 Jan 29.

Division of Molecular Pathology, Haemato-Oncology Research Unit, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12218DOI Listing
April 2013

MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA.

Biol Open 2012 Sep 11;1(9):863-73. Epub 2012 Jul 11.

Institute for Cell and Molecular Biosciences, The Medical School, Newcastle University , Newcastle upon Tyne NE2 4HH , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/bio.20121834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507232PMC
September 2012

A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.

Clin Cancer Res 2011 Oct 19;17(19):6347-55. Epub 2011 Aug 19.

Section of Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-0994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866998PMC
October 2011

Renal safety of ibandronate.

Authors:
Graham H Jackson

Oncologist 2005 ;10 Suppl 1:14-8

Department of Haematology, University of Newcastle-Upon-Tyne, R.V.I., Queen Victoria Road, Newcastle-Upon-Tyne, United Kingdom, NE1 4LP.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.10-90001-14DOI Listing
February 2006

The fate of human Langerhans cells in hematopoietic stem cell transplantation.

J Exp Med 2006 Jan 3;203(1):27-33. Epub 2006 Jan 3.

Haematological Sciences, University of Newcastle, Newcastle upon Tyne NE2 4HH, England, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20051787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118090PMC
January 2006

Use of fludarabine in the treatment of acute myeloid leukemia.

Authors:
Graham H Jackson

Hematol J 2004 ;5 Suppl 1:S62-7

Department of Haematology, R.V.I., Queen Victoria Road, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200392DOI Listing
December 2004

DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.

Carcinogenesis 2004 Oct 13;25(10):1795-803. Epub 2004 May 13.

Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgh187DOI Listing
October 2004

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

Blood 2004 Jun 9;103(12):4659-65. Epub 2004 Mar 9.

School of Cell and Molecular Biosciences, University of Newcastle-upon-Tyne Medical School, Newcastle-upon-Tyne NE2 4HH, United Kingdom.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-07-25
Publisher Site
http://dx.doi.org/10.1182/blood-2003-07-2527DOI Listing
June 2004

Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation.

Transplantation 2003 Dec;76(12):1742-9

Department of Haematology, Royal Victoria Infirmary, University of Newcastle, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.TP.0000092496.05951.D5DOI Listing
December 2003

Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Br J Haematol 2003 Sep;122(5):778-87

Haematological Sciences, School of Clinical Laboratory Sciences, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK.

View Article

Download full-text PDF

Source
September 2003

Acute myeloid leukaemia: optimising treatment in elderly patients.

Drugs Aging 2002 ;19(8):571-81

Department of Haematology, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00002512-200219080-00003DOI Listing
November 2002

Interleukin-10 modulation of alloreactivity and graft-versus-host reactions.

Transplantation 2002 Sep;74(6):772-8

Department of Haematology, School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.TP.0000026253.67448.BEDOI Listing
September 2002

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.

Nat Med 2002 Apr;8(4):410-4

University Department of Haematology, Royal Victoria Infirmary, University of Newcastle, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0402-410DOI Listing
April 2002